These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 38323311)

  • 81. Triple blockade of Ido-1, PD-L1 and MEK as a potential therapeutic strategy in NSCLC.
    Della Corte CM; Ciaramella V; Ramkumar K; Vicidomini G; Fiorelli A; Nardone V; Cappabianca S; Cozzolino I; Zito Marino F; Di Guida G; Wang Q; Cardnell R; Gay CM; Ciardiello D; Martinelli E; Troiani T; Martini G; Napolitano S; Wang J; Byers LA; Ciardiello F; Morgillo F
    J Transl Med; 2022 Nov; 20(1):541. PubMed ID: 36419183
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Restoration of p53 activity via intracellular protein delivery sensitizes triple negative breast cancer to anti-PD-1 immunotherapy.
    Yang Z; Sun JK; Lee MM; Chan MK
    J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36104100
    [TBL] [Abstract][Full Text] [Related]  

  • 83. MiR155 sensitized B-lymphoma cells to anti-PD-L1 antibody via PD-1/PD-L1-mediated lymphoma cell interaction with CD8+T cells.
    Zheng Z; Sun R; Zhao HJ; Fu D; Zhong HJ; Weng XQ; Qu B; Zhao Y; Wang L; Zhao WL
    Mol Cancer; 2019 Mar; 18(1):54. PubMed ID: 30925928
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Chemoradiation-Induced Alteration of Programmed Death-Ligand 1 and CD8
    Lim YJ; Koh J; Kim S; Jeon SR; Chie EK; Kim K; Kang GH; Han SW; Kim TY; Jeong SY; Park KJ; Wu HG
    Int J Radiat Oncol Biol Phys; 2017 Dec; 99(5):1216-1224. PubMed ID: 29165286
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Oncolytic poxvirus CF33-hNIS-ΔF14.5 favorably modulates tumor immune microenvironment and works synergistically with anti-PD-L1 antibody in a triple-negative breast cancer model.
    Chaurasiya S; Yang A; Kang S; Lu J; Kim SI; Park AK; Sivanandam V; Zhang Z; Woo Y; Warner SG; Fong Y
    Oncoimmunology; 2020; 9(1):1729300. PubMed ID: 32158622
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Sequential Anti-PD1 Therapy Following Dendritic Cell Vaccination Improves Survival in a HER2 Mammary Carcinoma Model and Identifies a Critical Role for CD4 T Cells in Mediating the Response.
    Kodumudi KN; Ramamoorthi G; Snyder C; Basu A; Jia Y; Awshah S; Beyer AP; Wiener D; Lam L; Zhang H; Greene MI; Costa RLB; Czerniecki BJ
    Front Immunol; 2019; 10():1939. PubMed ID: 31475002
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Licochalcone A inhibits interferon-gamma-induced programmed death-ligand 1 in lung cancer cells.
    Yuan LW; Jiang XM; Xu YL; Huang MY; Chen YC; Yu WB; Su MX; Ye ZH; Chen X; Wang Y; Lu JJ
    Phytomedicine; 2021 Jan; 80():153394. PubMed ID: 33130472
    [TBL] [Abstract][Full Text] [Related]  

  • 88. A dual-functional oncolytic adenovirus ZD55-aPD-L1 scFv armed with PD-L1 inhibitor potentiates its antitumor activity.
    Mei S; Peng S; Vong EG; Zhan J
    Int Immunopharmacol; 2024 Feb; 128():111579. PubMed ID: 38278066
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Regulation of ROS in myeloid-derived suppressor cells through targeting fatty acid transport protein 2 enhanced anti-PD-L1 tumor immunotherapy.
    Adeshakin AO; Liu W; Adeshakin FO; Afolabi LO; Zhang M; Zhang G; Wang L; Li Z; Lin L; Cao Q; Yan D; Wan X
    Cell Immunol; 2021 Apr; 362():104286. PubMed ID: 33524739
    [TBL] [Abstract][Full Text] [Related]  

  • 90. The PD-L1/4-1BB Bispecific Antibody-Anticalin Fusion Protein PRS-344/S095012 Elicits Strong T-Cell Stimulation in a Tumor-Localized Manner.
    Peper-Gabriel JK; Pavlidou M; Pattarini L; Morales-Kastresana A; Jaquin TJ; Gallou C; Hansbauer EM; Richter M; Lelievre H; Scholer-Dahirel A; Bossenmaier B; Sancerne C; Riviere M; Grandclaudon M; Zettl M; Bel Aiba RS; Rothe C; Blanc V; Olwill SA
    Clin Cancer Res; 2022 Aug; 28(15):3387-3399. PubMed ID: 35121624
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Targeting 4-1BB and PD-L1 induces potent and durable antitumor immunity in B-cell lymphoma.
    Wang Y; Zhang X; Xu C; Nan Y; Fan J; Zeng X; Kwon BS; Ju D
    Front Immunol; 2022; 13():1004475. PubMed ID: 36544785
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Ultrasound -Induced Thermal Effect Enhances the Efficacy of Chemotherapy and Immunotherapy in Tumor Treatment.
    Xiang Y; Tang L; Pang H; Xu H; He Y; Feng Y; Ju L; Zhang L; Wang D
    Int J Nanomedicine; 2024; 19():6677-6692. PubMed ID: 38975322
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Impacts of combining anti-PD-L1 immunotherapy and radiotherapy on the tumour immune microenvironment in a murine prostate cancer model.
    Philippou Y; Sjoberg HT; Murphy E; Alyacoubi S; Jones KI; Gordon-Weeks AN; Phyu S; Parkes EE; Gillies McKenna W; Lamb AD; Gileadi U; Cerundolo V; Scheiblin DA; Lockett SJ; Wink DA; Mills IG; Hamdy FC; Muschel RJ; Bryant RJ
    Br J Cancer; 2020 Sep; 123(7):1089-1100. PubMed ID: 32641865
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Radiotherapy enhances CXCR3
    Wang CL; Ho AS; Chang CC; Sie ZL; Peng CL; Chang J; Cheng CC
    Cancer Immunol Immunother; 2023 Jun; 72(6):1865-1880. PubMed ID: 36688994
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Celastrol Elicits Antitumor Effects through Inducing Immunogenic Cell Death and Downregulating PD-L1 in ccRCC.
    Li HF; Zhu N; Wu JJ; Shi YN; Gu J; Qin L
    Curr Pharm Des; 2024; 30(16):1265-1278. PubMed ID: 38584553
    [TBL] [Abstract][Full Text] [Related]  

  • 96. [Efficacy of combined treatment with pirfenidone and PD-L1 inhibitor in mice bearing ectopic bladder cancer xenograft].
    Chen S; Zhang S; Fan W; Sun W; Liu B; Liu J; Guo Y
    Nan Fang Yi Ke Da Xue Xue Bao; 2024 Feb; 44(2):210-216. PubMed ID: 38501405
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Lipid Nanoparticular Codelivery System for Enhanced Antitumor Effects by Ferroptosis-Apoptosis Synergistic with Programmed Cell Death-Ligand 1 Downregulation.
    Cao W; Zhang X; Feng Y; Li R; Lu A; Li Z; Yu F; Sun L; Wang J; Wang Z; He H
    ACS Nano; 2024 Jul; 18(26):17267-17281. PubMed ID: 38871478
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Opaganib (ABC294640) Induces Immunogenic Tumor Cell Death and Enhances Checkpoint Antibody Therapy.
    Maines LW; Keller SN; Smith CD
    Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38069222
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Silymarin suppresses proliferation and PD-L1 expression in colorectal cancer cells and increases inflammatory CD8+ cells in tumor-bearing mice.
    Al-Haideri M
    Clin Res Hepatol Gastroenterol; 2024 Oct; 48(8):102425. PubMed ID: 39048076
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Imaging Calreticulin for Early Detection of Immunogenic Cell Death During Anticancer Treatment.
    Kim DY; Pyo A; Yun M; Thangam R; You SH; Zhang Y; Jung YR; Nguyen DH; Venu A; Kim HS; Yoon MS; Hong Y; Min JJ
    J Nucl Med; 2021 Jul; 62(7):956-960. PubMed ID: 33509975
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.